Scleroderma: Difference between revisions

Jump to navigation Jump to search
Line 54: Line 54:
== Therapy ==
== Therapy ==


There is no cure for every patient with scleroderma, though there is treatment for some of the symptoms, including drugs that soften the skin and reduce inflammation. Some patients may benefit from exposure to heat.<ref>{{cite journal |author=Oliver GF, Winkelmann RK |title=The current treatment of scleroderma |journal=Drugs |volume=37 |issue=1 |pages=87-96 |year=1989 |pmid=2651089 |doi=}}</ref>


Digital ulcerations and pulmonary hypertension can be helped by [[prostacyclin]] (iloprost) infusion. Iloprost being a drug which increases blood flow by relaxing the arterial wall.<ref>{{cite journal |author=Zandman-Goddard G, Tweezer-Zaks N, Shoenfeld Y |title=New therapeutic strategies for systemic sclerosis--a critical analysis of the literature |journal=Clin. Dev. Immunol. |volume=12 |issue=3 |pages=165-73 |year=2005 |pmid=16295521 |doi=}}</ref>
===Topical/symptomatic===
Topical treatment for the skin changes of scleroderma do not alter the disease course, but may improve pain and ulceration. A range of [[NSAID]]s (nonsteroidal anti-inflammatory drugs) can be used to ease painful symptoms, such as [[naproxen]]. There is limited benefit from [[glucocorticoid|steroids]] such as prednisone. Episodes of Raynaud's phenomenon sometimes respond to [[nifedipine]] or other calcium channel blockers; severe digital ulceration may respond to [[prostacyclin]] analogue [[iloprost]], and the dual endothelin-receptor antagonist [[bosentan]] may be beneficial for Raynaud's phenomenon.<ref name=Zandberg>{{cite journal |author=Zandman-Goddard G, Tweezer-Zaks N, Shoenfeld Y |title=New therapeutic strategies for systemic sclerosis--a critical analysis of the literature |journal=Clin. Dev. Immunol. |volume=12 |issue=3 |pages=165–73 |year=2005 |pmid=16295521 |doi=}} {{PMC|2275417}}</ref> The skin tightness may be treated systemically with [[methotrexate]] and [[cyclosporin]].<ref name=Zandberg/> If there is esophageal dysmotility (in CREST or systemic sclerosis), care must be taken with NSAIDs as they are gastric irritants, and so a [[proton pump inhibitor]] (PPI) such as [[omeprazole]] can be given in conjunction.
===Kidney disease===
Scleroderma renal crisis, the occurrence of [[acute renal failure]] and [[malignant hypertension]] (very high blood pressure with evidence of organ damage) in people with scleroderma, is effectively treated with drugs from the class of the [[ACE inhibitor]]s. The benefit of ACE inhibitors extends even to those who have to commence [[hemodialysis|dialysis]] to treat their kidney disease, and may give sufficient benefit to allow the discontinuation of renal replacement therapy.<ref name=Zandberg/> [[ACE inhibitors]] are also used for [[prophylaxis]],<ref name=jimenez/><ref name=steen11033587/> and [[renal transplantation]]. Transplanted kidneys are known to be affected by scleroderma and patients with early onset renal disease (within one year of the scleroderma diagnosis) are thought to have the highest risk for recurrence.<ref>Pham PT, Pham PC, Danovitch GM, Gritsch HA, Singer J, Wallace WD, Hayashi R, Wilkinson AH. Predictors and risk factors for recurrent scleroderma renal crisis in the kidney allograft: case report and review of the literature. Am J Transplant. 2005 Oct;5(10):2565-9. PMID 16162209.</ref>
===Lung disease and pulmonary hypertension===
Active alveolitis is often treated with pulses of [[cyclophosphamide]], often together with a small dose of steroids. The benefit of this intervention is modest.<ref>{{cite journal |author=Tashkin DP, Elashoff R, Clements PJ, ''et al'' |title=Cyclophosphamide versus placebo in scleroderma lung disease |journal=N. Engl. J. Med. |volume=354 |issue=25 |pages=2655–66 |year=2006 |month=June |pmid=16790698 |doi=10.1056/NEJMoa055120 |url=http://content.nejm.org/cgi/content/full/354/25/2655}}</ref><ref>{{cite journal |author=Hoyles RK, Ellis RW, Wellsbury J, ''et al'' |title=A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma |journal=Arthritis Rheum. |volume=54 |issue=12 |pages=3962–70 |year=2006 |month=December |pmid=17133610 |doi=10.1002/art.22204 | url=http://www3.interscience.wiley.com/cgi-bin/fulltext/113490260/HTMLSTART}}</ref>
Pulmonary hypertension may be treated with [[epoprostenol]], [[bosentan]] and possibly aerolized iloprost.<ref name=Zandberg/>


===Experimental treatments===
===Experimental treatments===

Revision as of 20:58, 30 August 2012

Template:DiseaseDisorder infobox

Scleroderma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Scleroderma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Scleroderma On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Scleroderma

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Scleroderma

CDC on Scleroderma

Scleroderma in the news

Blogs on Scleroderma

Directions to Hospitals Treating Scleroderma

Risk calculators and risk factors for Scleroderma

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor-In-Chief: Cafer Zorkun, M.D., Ph.D. [2]

For patient information click here

Synonyms and keywords: Systemic sclerosis

Click here for The Heart in Scleroderma

Overview

Epidemiology

Pathophysiology

Etiology

Types of Scleroderma

Diagnosis

Diagnosis is by clinical suspicion, presence of autoantibodies (specifically anti-centromere and anti-scl70/anti-topoisomerase antibodies) and occasionally by biopsy. Of the antibodies, 90% have a detectable anti-nuclear antibody. Anti-centromere antibody is more common in the limited form (80-90%) than in the systemic form (10%), and anti-scl70 is more common in the diffuse form (30-40%) and in African-American patients (who are more susceptible to the systemic form).[1]

In 1980 the American College of Rheumatology agreed upon diagnostic criteria for scleroderma.[2]

Diffuse scleroderma can cause musculoskeletal, pulmonary, gastrointestinal, renal and other complications.[3]Patients with larger amounts of cutaneous involvement are more likely to have involvement of the internal tissues and organs.

Cardiovascular Symptoms

Skin Symptoms

Musculoskeletal System Related Symptoms

Respiratory System Symptoms

Gastrointestinal System Related Symptoms

Renal Symptoms

Therapy

Experimental treatments

Case Studies

Case #1

References

  1. Jimenez SA, Derk CT (2004). "Following the molecular pathways toward an understanding of the pathogenesis of systemic sclerosis". Ann. Intern. Med. 140 (1): 37–50. PMID 14706971.
  2. "Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee". Arthritis Rheum. 23 (5): 581–90. PMID 7378088. Text "year:1980 " ignored (help) Available online at "Criteria for the Classification of Systemic Sclerosis 1980". Text " accessdate:5 August 2007" ignored (help)

External links

Template:Diseases of the musculoskeletal system and connective tissue

de:Sklerodermie it:Sclerodermia he:סקלרודרמה nl:Sclerodermie sk:Sklerodermia sv:Sklerodermi


Template:WikiDoc Sources